Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7551 to 7600 of 8236 results

  1. Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]

    In development Reference number: GID-TA11253 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]

    In development Reference number: GID-TA11001 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]

    In development Reference number: GID-TA11302 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

    Technology appraisal guidance
    Discontinued

  5. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    In development Reference number: GID-TA11021 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    In development Reference number: GID-TA11647 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

    In development Reference number: GID-TA11624 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099

    In development Reference number: GID-TA11640 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Cendakimab for treating eosinophilic oesophagitis in people 12 years TS ID 12088

    Discontinued Reference number: GID-TA11702

    Technology appraisal guidance
    Discontinued

  10. OrganOx metra for liver transplant [ID5116]

    Discontinued Reference number: GID-TA11035

    Technology appraisal guidance
    Discontinued

  11. Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]

    Discontinued Reference number: GID-TA10764

    Technology appraisal guidance
    Discontinued

  12. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued Reference number: GID-NG10397

    NICE guideline
    Discontinued

  13. Ipatasertib with fulvestrant for treating oestrogen-receptor positive HER2-negative advanced breast cancer after CDK 4/6 and aromatase inhibitor treatment [ID12194]

    In development Reference number: GID-TA11771 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. The Assurance Nasal Alar SpO2 Sensor (discontinued)

    Discontinued Reference number: GID-MT510

    Medical technologies guidance
    Discontinued

  15. Abicipar pegol for treating wet age-related macular degeneration [ID1533]

    In development Reference number: GID-TA10511 Expected publication date: TBC

    Technology appraisal guidance
    In development

  16. Surgical site infections: prevention and treatment - Update

    Discontinued Reference number: GID-NG10374

    NICE guideline
    Discontinued

  17. Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]

    In development Reference number: GID-TA11443 Expected publication date: TBC

    Technology appraisal guidance
    In development

  18. Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152]

    In development Reference number: GID-TA11089 Expected publication date: TBC

    Technology appraisal guidance
    In development

  19. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273]

    In development Reference number: GID-TA11301 Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473

    In development Reference number: GID-TA11582 Expected publication date: TBC

    Technology appraisal guidance
    In development

  22. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Vosoritide for treating achondroplasia in people 4 months and over [ID6488]

    In development Reference number: GID-TA11528 Expected publication date: TBC

    Technology appraisal guidance
    In development

  24. Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

    In development Reference number: GID-TA11607 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  25. Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]

    In development Reference number: GID-TA11166 Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. MRI guided focussed ultrasound for chronic pain

    Discontinued Reference number: GID-IP1043

    Interventional procedures guidance
    Discontinued

  27. Prostate cancer (prevention) - dutasteride [ID75]

    Discontinued Reference number: GID-TAG409

    Technology appraisal guidance
    Discontinued

  28. Sunitinib in combination with capecitabine for the treatment of advanced and/or metastatic breast cancer [ID319]

    Discontinued Reference number: GID-TAG410

    Technology appraisal guidance
    Discontinued

  29. Asthma: diagnosis, monitoring and chronic asthma management (NG80)

    This guideline has been updated and replaced by NICE guideline NG245.

    NICE guideline
    Last updated
    22 March 2021

  30. Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642]

    Discontinued Reference number: GID-TA11855

    Technology appraisal guidance
    Discontinued

  31. Concizumab for treating haemophilia A or B in people 12 years and over with inhibitors [ID6665]

    In development Reference number: GID-TA11888 Expected publication date: TBC

    Technology appraisal guidance
    In development

  32. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]

    In development Reference number: GID-TA11556 Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]

    In development Reference number: GID-TA11781 Expected publication date: TBC

    Technology appraisal guidance
    In development

  34. SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)

    Discontinued Reference number: GID-MT516

    Medical technologies guidance
    Discontinued

  35. Axatilimab for treating active chronic graft-versus-host disease after 2 or more systemic treatments in people 2 years and over [ID6570]

    In development Reference number: GID-TA11745 Expected publication date: TBC

    Technology appraisal guidance
    In development

  36. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  37. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development Reference number: GID-TA11093 Expected publication date: TBC

    Technology appraisal guidance
    In development

  38. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development Reference number: GID-TA11074 Expected publication date: TBC

    Technology appraisal guidance
    In development

  39. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development Reference number: GID-TA11146 Expected publication date: TBC

    Technology appraisal guidance
    In development

  40. Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726

    In development Reference number: GID-TA11015 Expected publication date: TBC

    Technology appraisal guidance
    In development

  41. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development Reference number: GID-TA11014 Expected publication date: TBC

    Technology appraisal guidance
    In development

  42. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development Reference number: GID-TA10568 Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

    Technology appraisal guidance
    Discontinued

  44. Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]

    Discontinued Reference number: GID-TA11026

    Technology appraisal guidance
    Discontinued

  45. Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

    Discontinued Reference number: GID-TA11000

    Technology appraisal guidance
    Discontinued

  46. Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]

    In development Reference number: GID-TA11163 Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]

    In development Reference number: GID-TA11433 Expected publication date: TBC

    Technology appraisal guidance
    In development

  48. Insulin icodec for treating type 2 diabetes [ID6175]

    In development Reference number: GID-TA11104 Expected publication date: TBC

    Technology appraisal guidance
    In development

  49. Abatacept for preventing moderate to severe acute graft-versus-host disease after haematopoietic stem cell transplant in people 6 years and over [ID6185]

    Discontinued Reference number: GID-TA10996

    Technology appraisal guidance
    Discontinued

  50. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    Discontinued Reference number: GID-TA10995

    Technology appraisal guidance
    Discontinued